SCHEMBL3203555

SCHEMBL3203555

Oc1ccc2cc(O)c(O)cc2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.62
ESR2 Q92731 11/20 0.56
ESR1 P03372 10/20 0.56
CYP3A4 P08684 2/20 0.56
ALOX15 P16050 1/20 0.56
TSHR P16473 1/20 0.56
HIF1A Q16665 1/20 0.56
HSD17B10 Q99714 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
ABL1 P00519 1/20 0.52
ABCB1 P08183 1/20 0.52
BCR P11274 1/20 0.52
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
HSD17B1 P14061 1/20 0.50
CYP2B6 P20813 1/20 0.50
CYP2C19 P33261 1/20 0.50
HSD17B2 P37059 1/20 0.50
F12 P00748 1/20 0.48
LCK P06239 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23371164 0.89 CYP1A2 (0.56) CYP1A2ESR2ESR1CYP3A4ALOX15
SCHEMBL29973107 0.88 CYP1A2 (0.68) CYP1A2ESR2ESR1CYP3A4ALOX15
SCHEMBL755928 0.88 CYP1A2 (0.68) CYP1A2ESR2ESR1CYP3A4ALOX15
SCHEMBL29405718 0.88 CYP1A2 (0.68) CYP1A2ESR2ESR1CYP3A4ALOX15
SCHEMBL392290 0.88 CYP1A2 (0.68) CYP1A2ESR2ESR1CYP3A4ALOX15
SCHEMBL3451975 0.88 CYP1A2 (0.78) CYP1A2ESR2ESR1CYP3A4ALOX15
SCHEMBL69484 0.87 CYP1A2 (0.77) CYP1A2ESR2ESR1CYP3A4ALOX15
SCHEMBL627219 0.87 CYP1A2 (0.77) CYP1A2ESR2ESR1CYP3A4ALOX15
SCHEMBL29364786 0.87 CYP1A2 (0.77) CYP1A2ESR2ESR1CYP3A4ALOX15
SCHEMBL20169579 0.86 CYP1A2 (0.48) CYP1A2ESR2ESR1CYP3A4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260133485-A1 METHOD FOR MANUFACTURING SEMICONDUCTOR SUBSTRATE AND UNDERLAYER FILM-FORMING COMPOSITION JSR CORPORATION (JP) 2026-05-14 US disclosed
US-20260093180-A1 METHOD FOR MANUFACTURING SEMICONDUCTOR SUBSTRATE AND COMPOSITION FOR FILM FORMATION JSR CORPORATION (JP) 2026-04-02 US disclosed
EP-4606882-A1 CLEANING SOLUTION, METHOD FOR CLEANING SUBSTRATE, AND METHOD FOR FORMING METAL-CONTAINING FILM SHIN-ETSU CHEMICAL CO., LTD. (JP) 2025-08-27 EP disclosed
US-20250263639-A1 Cleaning Solution, Method For Cleaning Substrate, And Method For Forming Metal Containing Film SHIN-ETSU CHEMICAL CO., LTD. (JP) 2025-08-21 US disclosed
EP-4600734-A1 PATTERN FORMING METHOD AND LAMINATE Shin-Etsu Chemical Co., Ltd. (JP) 2025-08-13 EP disclosed
US-20250246429-A1 Pattern Forming Method And Laminate SHIN-ETSU CHEMICAL CO., LTD. (JP) 2025-07-31 US disclosed
WO-2025079496-A1 METHOD FOR MANUFACTURING SEMICONDUCTOR SUBSTRATE JSR株式会社 2025-04-17 WO disclosed
WO-2025041533-A1 SEMICONDUCTOR SUBSTRATE PRODUCTION METHOD AND FILM-FORMING COMPOSITION JSR株式会社 2025-02-27 WO disclosed
WO-2025013817-A1 METHOD FOR MANUFACTURING SEMICONDUCTOR SUBSTRATE, AND UNDERLAYER FILM-FORMING COMPOSITION FOR FIRST METAL-CONTAINING RESIST JSR株式会社 2025-01-16 WO disclosed
US-20240369931-A1 METHOD OF MANUFACTURING SEMICONDUCTOR SUBSTRATE, METHOD FOR FORMING RESIST UNDERLAYER FILM, AND CLEANING LIQUID JSR CORPORATION (JP) 2024-11-07 US disclosed
US-20060014696-A1 Modulators of beta-amyloid peptide aggregation comprising D-amino acids PRAECIS PHARMACEUTICALS, INC. (US) 2006-01-19 US disclosed
EP-1586584-A1 Modulators of beta-amyloid peptide aggregation comprising D-amino acids Praecis Pharmaceuticals Incorporated (US) 2005-10-19 EP disclosed
EP-0929574-B1 MODULATORS OF beta-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS PRAECIS PHARM INC (US) 2005-06-29 EP disclosed
US-20050084464-A1 Method for reducing odor using metal-modified particles KIMBERLY-CLARK WORLDWIDE, INC. 2005-04-21 US disclosed
US-6689752-B2 AMINO-TERMINAL MODIFYING GROUPS INCLUDE CYCLIC, HETEROCYCLIC, POLYCYCLIC AND BRANCHED ALKYLS, AND CARBOXY-TERMINAL MODIFYING GROUPS INCLUDE AN AMIDE, AN ALKYL AMIDE, AN ARYL AMIDE OR A HYDROXY; TREATING ALZHEIMER'S DISEASE PRAECIS PHARMACEUTICALS, INCORPORATED 2004-02-10 US disclosed
EP-0810249-B1 Thermosetting resin composition, electrically insulated coil, electric rotating machine and method for producing same HITACHI LTD (JP) 2001-11-07 EP disclosed
US-5982056-A STATOR OF ROTATING MACHINE HITACHI, LTD. (JP) 1999-11-09 US disclosed
EP-0810249-A2 Thermosetting resin composition, electrically insulated coil, electric rotating machine and method for producing same HITACHI, LTD. (JP) 1997-12-03 EP disclosed
US-5208390-A Organic sulfonation catalysts for alkylation of aromatic polyols CHEVRON RESEARCH AND TECHNOLOGY COMPANY (US) 1993-05-04 US disclosed
US-4350534-A Fluid, stable formulations of copper phthalocyanine or indanthrone BASF AKTIENGESELLSCHAFT (DE) 1982-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260093180-A1 METHOD FOR MANUFACTURING SEMICONDUCTOR SUBSTRATE AND COMPOSITION FOR FILM FORMATION SMC4, TYR, SMC2 CYP1A2 297/4885ESR2 2855/4885ESR1 3058/4885
US-20050084464-A1 Method for reducing odor using metal-modified particles OR10J3, OR51E2, ORAI2 CYP1A2 4711/4885ESR2 2943/4885ESR1 3009/4885
US-20060014696-A1 Modulators of beta-amyloid peptide aggregation comprising D-amino acids APP, IAPP, BACE1 CYP1A2 4155/4885ESR2 1939/4885ESR1 3309/4885
US-20260133485-A1 METHOD FOR MANUFACTURING SEMICONDUCTOR SUBSTRATE AND UNDERLAYER FILM-FORMING COMPOSITION TWF2, TERF2, TPR CYP1A2 2496/4885ESR2 3352/4885ESR1 2434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.